AD Pipeline Update: Turn Therapeutics Launches Trial Evaluating Its Topical IL-36/IL-31 Inhibitor for Eczema
Turn Therapeutics is starting a randomized, double-blind, vehicle-controlled clinical trial evaluating its topical GX-03 formulation for the treatment of moderate-to-severe eczema (atopic dermatitis).